Preparation, pharmacokinetics and tumour-suppressive activity of berberine liposomes

Wang, Xinghui; Wang, Qiong; Liu, Zhihui; Zheng, Xiao

doi:10.1111/jphp.12692

Cited by 39 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with the in vitro data, we obtained the first in vivo evidence for the enhanced efficacy of the berberine combined with PEG-lip-DOX in tumor-bearing mice. Although the precise function of berberine for the enhancement of this anticancer effect by the combination with liposomal DOX is not clear at present, liposomalization of berberine 12) would be valuable future work to further enhance the combination effects. During the study, the body weight of all groups was monitored; however, none of the treatments affected the body weight very much (Fig.…”

Section: Resultsmentioning

confidence: 99%

Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice

Yahuafai¹,

Asai

Oku

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice

Yahuafai¹,

Asai

Oku

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…Thus, liposomes of 100–200 nm in size have been considered as suitable for their distribution in the three infected organs (liver, spleen and BM). Different methods have been previously used for the obtention of common BER liposomes, such as the pH gradient-film method [ 31 ] or ethanol injection method [ 18 ], with variable encapsulation efficacies (85 and 10.4%). In this study, we prepared liposomes by film-hydration method and homogenization of their size by sonication.…”

Section: Discussionmentioning

confidence: 99%

“…The pharmacokinetic characteristics of BER as well as its organ accumulation have been much more widely investigated in rats [ 31 , 54 ]. According to Cl value in rats, BER would present an intermediate rate of clearance [ 31 ], whereas it would be considered as very rapid in mice. Although LP-BER decreased the clearance of the drug by 10-fold, it was still very high.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Berberine-Loaded Liposomes for the Treatment of Leishmania infantum-Infected BALB/c Mice

et al. 2020

View full text Add to dashboard Cite

Berberine (BER)—an anti-inflammatory quaternary isoquinoline alkaloid extracted from plants—has been reported to have a variety of biologic properties, including antileishmanial activity. This work addresses the preparation of BER-loaded liposomes with the aim to prevent its rapid liver metabolism and improve the drug selective delivery to the infected organs in visceral leishmaniasis (VL). BER liposomes (LP-BER) displayed a mean size of 120 nm, negative Z-potential of −38 mV and loaded 6 nmol/μmol lipid. In vitro, the loading of BER in liposomes enhanced its selectivity index more than 7-fold by decreasing its cytotoxicity to macrophages. In mice, LP-BER enhanced drug accumulation in the liver and the spleen. Consequently, the liposomal delivery of the drug reduced parasite burden in the liver and spleen by three and one logarithms (99.2 and 93.5%), whereas the free drug only decreased the infection in the liver by 1-log. The organ drug concentrations—far from IC50 values— indicate that BER immunomodulatory activity or drug metabolites also contribute to the efficacy. Although LP-BER decreased 10-fold—an extremely rapid clearance of the free drug in mice—the value remains very high. Moreover, LP-BER reduced plasma triglycerides levels.

show abstract

“…To prolong the release and increase the bioavailability of BH, the administration of drug encapsulated in biodegradable polymeric nanoparticles has been investigated. For example, solid lipid nanoparticles (Wang et al, 2017), gold nanoparticles (Yu et al, 2016), and so on. Despite these, the reported nanodosage forms of BH still have low oral bioavailability and many side effects that need to be overcome (Su et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Autologous erythrocytes delivery of berberine hydrochloride with long-acting effect for hypolipidemia treatment

Cheng

Liu

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

Discovery of novel pharmacological effects of berberine hydrochloride (BH) has made its clinical application valuable. However, further development and applications of BH are hampered by its short halflife and the side effects associated with its intravenous (iv) injection. To improve the hypolipidemia efficacy and reduce side effects, we encapsulated BH into biocompatible red blood cells (RBCs) to explore its sustained-release effect by hypotonic pre-swelling method. From in vitro evaluation, BH loaded RBCs (BH-RBCs) presented similar morphology and osmotic fragility to native RBCs (NRBCs). After the loading process, the BH-RBCs maintained around 69% of Na þ /K þ-ATPase activity of NRBCs and phosphatidylserine externalization value of BH-RBCs was about 26.1 ± 2.9%. The survival test showed that the loaded cells could circulate in plasma for over 9 d. For in vivo evaluation, a series of tests including pharmacokinetics study and hypolipidemic effect were carried out to examine the long-acting effect of BH-RBCs. The results showed that the release of BH in the loaded cells could last for about 5 d and the hypolipidemic effect can still be observed on 5 d after injection. BH-loaded autologous erythrocytes seem to be a promising sustained releasing delivery system with long hypolipidemic effect.

show abstract

Preparation, pharmacokinetics and tumour-suppressive activity of berberine liposomes

Abstract: Our study suggested that BBR liposomes may provide a safe form of intravenous drug therapy for strengthening the antitumour effects of BBR.

Cited by 39 publications

References 20 publications

Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice

Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice

Berberine-Loaded Liposomes for the Treatment of Leishmania infantum-Infected BALB/c Mice

Autologous erythrocytes delivery of berberine hydrochloride with long-acting effect for hypolipidemia treatment

Contact Info

Product

Resources

About